These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 35144640)

  • 1. Causes, clinical findings and therapeutic options in chylomicronemia syndrome, a special form of hypertriglyceridemia.
    Paragh G; Németh Á; Harangi M; Banach M; Fülöp P
    Lipids Health Dis; 2022 Feb; 21(1):21. PubMed ID: 35144640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment.
    Chait A; Eckel RH
    Ann Intern Med; 2019 May; 170(9):626-634. PubMed ID: 31035285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comprehensive Update on the Chylomicronemia Syndrome.
    Goldberg RB; Chait A
    Front Endocrinol (Lausanne); 2020; 11():593931. PubMed ID: 33193106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial Chylomicronemia Syndrome: A Clinical Guide For Endocrinologists.
    Falko JM
    Endocr Pract; 2018 Aug; 24(8):756-763. PubMed ID: 30183397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analyses of familial chylomicronemia syndrome in Pereira, Colombia 2010-2020: a cross-sectional study.
    Rodriguez FH; Estrada JM; Quintero HMA; Nogueira JP; Porras-Hurtado GL
    Lipids Health Dis; 2023 Mar; 22(1):43. PubMed ID: 36978188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in familial chylomicronemia syndrome diagnosis and management across Latin American countries: An expert panel discussion.
    Santos RD; Lorenzatti A; Corral P; Nogueira JP; Cafferata AM; Aimone D; Lourenço CM; Izar MC; Lima JG; Lottenberg AM; Alonso R; Garay K; Morales AR; Vargas-Uricoechea H; Peña CAC; Roman-González A
    J Clin Lipidol; 2021; 15(5):620-624. PubMed ID: 34920815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome.
    Chaudhry R; Viljoen A; Wierzbicki AS
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):589-598. PubMed ID: 29842811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Encephalopathy in type I hyperlipidemia.
    Onal H; Atugluzeybek C; Alhaj S; Altun G
    Indian Pediatr; 2007 Apr; 44(4):306-8. PubMed ID: 17468530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chylomicronemia due to LPL inhibitor].
    Okubo M
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():32-3. PubMed ID: 11347085
    [No Abstract]   [Full Text] [Related]  

  • 10. Diagnostic algorithm for familial chylomicronemia syndrome.
    Stroes E; Moulin P; Parhofer KG; Rebours V; Löhr JM; Averna M
    Atheroscler Suppl; 2017 Jan; 23():1-7. PubMed ID: 27998715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial chylomicronemia in a nine months old infant.
    Lone SW; Imdad A; Billoo AG
    J Coll Physicians Surg Pak; 2008 Oct; 18(10):655-6. PubMed ID: 18940129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics of Hypertriglyceridemia.
    Dron JS; Hegele RA
    Front Endocrinol (Lausanne); 2020; 11():455. PubMed ID: 32793115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment.
    Gallo A; Béliard S; D'Erasmo L; Bruckert E
    Curr Atheroscler Rep; 2020 Aug; 22(11):63. PubMed ID: 32852651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial chylomicronemia and multifactorial chylomicronemia.
    Muñiz-Grijalvo O; Diaz-Diaz JL
    Clin Investig Arterioscler; 2021 May; 33 Suppl 2():56-62. PubMed ID: 34006355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chylomicronemia syndrome].
    Francis A; Levy Y
    Harefuah; 2002 Feb; 141(2):201-3, 221, 220. PubMed ID: 11905095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and functional characterization of familial chylomicronemia syndrome.
    Teramoto R; Tada H; Kawashiri MA; Nohara A; Nakahashi T; Konno T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K
    Atherosclerosis; 2018 Feb; 269():272-278. PubMed ID: 29153744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A lipoprotein lipase-GPI-anchored high-density lipoprotein-binding protein 1 fusion lowers triglycerides in mice: Implications for managing familial chylomicronemia syndrome.
    Nimonkar AV; Weldon S; Godbout K; Panza D; Hanrahan S; Cubbon R; Xu F; Trauger JW; Gao J; Voznesensky A
    J Biol Chem; 2020 Mar; 295(10):2900-2912. PubMed ID: 31645434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical, biochemical and molecular analysis of two infants with familial chylomicronemia syndrome.
    Zhang Y; Zhou J; Zheng W; Lan Z; Huang Z; Yang Q; Liu C; Gao R; Zhang Y
    Lipids Health Dis; 2016 May; 15():88. PubMed ID: 27153815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rare Variants in Triglycerides-Related Genes Increase Pancreatitis Risk in Multifactorial Chylomicronemia Syndrome.
    Paquette M; Amyot J; Fantino M; Baass A; Bernard S
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3473-e3482. PubMed ID: 34019660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting APOC3 in the familial chylomicronemia syndrome.
    Gaudet D; Brisson D; Tremblay K; Alexander VJ; Singleton W; Hughes SG; Geary RS; Baker BF; Graham MJ; Crooke RM; Witztum JL
    N Engl J Med; 2014 Dec; 371(23):2200-6. PubMed ID: 25470695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.